Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase ...

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...

Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an ...

According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

A symbol of American pharmaceutical innovation for nearly two centuries, Pfizer now faces the challenges of AI adoption and ...

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

Vertex Pharmaceuticals announced the FDA has accepted its biologics license application submission for povetacicept, an ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus after recent share price moves, with the stock ...